Tag: Genmab
Zai Lab to Commercialize and Expand Patient Access to Tisotumab...
Zai Lab, a patient focused, global biopharma company committed to driving the next wave of healthcare innovation confirmed that it had signed an exclusive collaboration and...
Promising Preliminary Data on Tisotumab Vedotin in Patients with Head and...
Preliminary data from the innovaTV 207 global, open-label, multicenter phase 2 trial of tisotumab vedotin (Tivdak®; Seagen and Genmab) as a monotherapy in patients...
ESMO 2019: Seattle Genetics to Present Initial Data from a Phase...
Less than a week before the start of the annual meeting of the European Society for Medical Oncology (ESMO), to be held September 27...
Phase II Trial of Tisotumab Vedotin in Advanced Cervical Cancer Provides...
Genmab and Seattle Genetics confirmed their decision to start a Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer....
Tisotumab vedotin Demonstrates Encouraging Response Rate and a Manageable Safety Profile...
Preliminary clinical data for tisotumab vedotin, also known as HuMax®-TF-ADC from a Genmab-sponsored phase I/II clinical trial (GEN 701) were featured today in an...
Seattle Genetics to Co-develop Tisotumab Vedodin with Genmab for the Treatment...
Genmab, an international biotechnology company headquartered in Copenhagen, Denmark, and Seattle Genetics, confirmed that Seattle Genetics has exercised its option to co-develop tisotumab vedotin. The...
ADCT-301 – A Novel Antibody-drug Conjugate Against Lymphomas – Moves Into...
ADC Therapeutics Sarl (Epalinges, Switzerland), a company involved in the development of antibody-drug conjugates against solid and hematological cancers, has filed an Investigational New Drug application or...
ADC Therapeutics and Genmab Agree to Develop Antibody-drug Conjugate
Earlier this week Swiss-based oncology drug development company ADC Therapeutics Sarl and Danish Genmab A/S agreed to develop a new antibody-drug conjugate (ADC) combining HuMax®-TAC antibody...
